Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-fibrotic and molecular effects of rifaximin in alcoholic liver disease
2014-001856-51Phase 4Completed
- Sponsor
- Aleksander Krag
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in alcoholic liver disease (ALD) and hepatic fibrosis comparing rifaximin with placebo (2 arms). Primary endpoint: Improvement in Ishak fibrosis score. Started Jun 2014; status: completed.
02
Drugs
rifaximin
03
Conditions
alcoholic liver disease (ALD)hepatic fibrosis
Beyond the preview
Go deeper on 2014-001856-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001856-51.